DeepMed Research

GENENTECH, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1976-01-01

Employees: 11.1K

Market Cap: -

Website: http://www.gene.com

Clinical Trials

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Leucovorin
Drug: Irinotecan
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2011-06-16

Last Posted Date: 2016-08-11

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 376

Registration Number: NCT01374425

Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Phase 2

Completed

Conditions: Non-Squamous Non-Small Cell Lung Cancer

Interventions: Drug: MEGF0444A
Drug: bevacizumab
Drug: carboplatin
Drug: paclitaxel
Drug: placebo

First Posted Date: 2011-06-03

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 104

Registration Number: NCT01366131

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 3

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Placebo
Drug: Pirfenidone

First Posted Date: 2011-06-03

Last Posted Date: 2017-04-05

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 555

Registration Number: NCT01366209

Locations: 🇺🇸
InterMune Inc., Brisbane, California, United States

Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer

Interventions: Drug: DNIB0600A

First Posted Date: 2011-06-02

Last Posted Date: 2017-06-07

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 87

Registration Number: NCT01363947

Locations: 🇺🇸
HonorHealth Research Institute - Pima Center, Scottsdale, Arizona, United States
🇪🇸
Hospital del Mar; Servicio de Oncologia, Barcelona, Spain
🇪🇸
Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain

and more 4 locations

Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: MFGR1877S

First Posted Date: 2011-06-01

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 24

Registration Number: NCT01363024

Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Enzalutamide
Drug: Docetaxel
Drug: 5-FU
Drug: Ipatasertib
Drug: Paclitaxel
Drug: Leucovorin
Drug: Oxaliplatin

First Posted Date: 2011-05-30

Last Posted Date: 2022-01-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 122

Registration Number: NCT01362374

Locations: 🇫🇷
Institut Gustave Roussy; Departement Oncologie Medicale, Villejuif, France
🇺🇸
Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 8 locations

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: GDC-0425
Drug: gemcitabine

First Posted Date: 2011-05-25

Last Posted Date: 2017-04-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 40

Registration Number: NCT01359696

Locations: 🇺🇸
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
🇺🇸
Karmanos Cancer Institute.., Detroit, Michigan, United States
🇫🇷
Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo, Villejuif, France

Evaluating the Safety and Tolerability of GDC-0349 in Patients With Locally Advanced or Metastatic Solid Tumors or Non Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma, Solid Tumor

Interventions: Drug: GDC-0349

First Posted Date: 2011-05-19

Last Posted Date: 2016-11-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 10

Registration Number: NCT01356173

A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: MABT5102A
Drug: placebo

First Posted Date: 2011-04-28

Last Posted Date: 2017-07-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 448

Registration Number: NCT01343966

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
Pharmacology Research Inst, Newport Beach, California, United States
🇺🇸
Margolin Brain Institute, Fresno, California, United States

and more 87 locations

Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: placebo
Drug: rhuMAb Beta7

First Posted Date: 2011-04-18

Last Posted Date: 2016-08-12

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 124

Registration Number: NCT01336465

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy